Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates
作者:Mihirbaran Mandal、Yusheng Wu、Jeffrey Misiaszek、Guoqing Li、Alexei Buevich、John P. Caldwell、Xiaoxiang Liu、Robert D. Mazzola、Peter Orth、Corey Strickland、Johannes Voigt、Hongwu Wang、Zhaoning Zhu、Xia Chen、Michael Grzelak、Lynn A. Hyde、Reshma Kuvelkar、Prescott T. Leach、Giuseppe Terracina、Lili Zhang、Qi Zhang、Maria S. Michener、Brad Smith、Kathleen Cox、Diane Grotz、Leonard Favreau、Kaushik Mitra、Irina Kazakevich、Brian A. McKittrick、William Greenlee、Matthew E. Kennedy、Eric M. Parker、Jared N. Cumming、Andrew W. Stamford
DOI:10.1021/acs.jmedchem.5b01995
日期:2016.4.14
We describe successful efforts to optimize the in vivo profile and address off-target liabilities of a series of BACE1 inhibitors represented by 6 that embodies the recently validated fused pyrrolidine iminopyrimidinone scaffold. Employing structure-based design, truncation of the cyanophenyl group of 6 that binds in the S3 pocket of BACE1 followed by modification of the thienyl group in S1 was pursued
我们描述了成功的努力,以优化体内概况和解决由6代表的一系列BACE1抑制剂的脱靶负债,这些抑制剂体现了最近验证的融合的吡咯烷亚氨基嘧啶酮支架。通过基于结构的设计,研究了在BACE1的S3口袋中结合的6个氰基苯基的截短,然后对S1中的噻吩基进行了修饰。优化结合在BACE1的S2'–S2''口袋中的嘧啶取代基的作用是对该系列中的早期类似物进行时间依赖性的CYP3A4抑制,并赋予了较高的BACE1亲和力。这些努力导致发现了二氟苯基类似物9(MBi-4),可有效降低CSF和皮质Aβ40在单次口服后,大鼠和食蟹猴中都会出现这种情况。化合物9代表了BACE抑制剂中独特的分子形状,据报道该化合物可有效降低非啮齿类临床前物种的中心Aβ。